Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

8.33USD
25 Apr 2018
Change (% chg)

$-0.13 (-1.54%)
Prev Close
$8.46
Open
$8.48
Day's High
$8.48
Day's Low
$8.22
Volume
18,324
Avg. Vol
44,549
52-wk High
$39.85
52-wk Low
$7.41

Select another date:

Mon, Mar 12 2018

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

Select another date: